AAO: CMS Payment Cuts For Eye Drug Counterproductive, Group Says

medpageToday

The recent cut in Medicare reimbursement for intravitreal bevacizumab (Avastin) will hurt both patients and taxpayers by forcing a shift to more expensive options, according to American Academy of Ophthalmology officials.
  • <<
  • >>

Comments